TAR001

About TargImmune Therapeutics

TargImmune Therapeutics is a private, pre-clinical stage biotech developing a first-in-class targeted nucleic acid delivery platform known as Targeted Apoptosis and Immune Modulators (TAIMs). The platform utilizes synthetic nanoparticles to deliver interchangeable nucleic acid payloads, such as double-stranded RNA (dsRNA), directly to tumors, inducing both cancer cell death and immune modulation. The lead program, TAR001, targets EGFR-overexpressing cancers and is on track for an IND/CTA filing in the first half of 2024, with the platform holding potential for application beyond oncology.

Therapeutic Areas

Other EGFR-positive solid tumors Drugs